Clinical trial register · Israel

Clinical Trials in Petah Tikva, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Israel and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2426 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:18 UTC

2426

Studies in scope

all four open statuses

1233

Recruiting now

open to new participants

457

Lead sponsors

across recruiting studies

Top sites

Jerusalem 838 Haifa 739 Tel Aviv 695 Ramat Gan 648 Petah Tikva 616

Trials with a site in Petah Tikva

Status

Study

Lead sponsor

Phase

Enrol

Sites in Israel

Start

Not yet open

A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

NCT07915219Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,500

Beersheba, Haifa, Jerusalem, Petah Tikva, Tel Aviv

2027-01-11

Not yet open

Stratification and Treatment in Early Psychosis Study -ASSIST

NCT07326124Treatment Resistant Psychosis, Psychosis

University of Oxford

Phase 3

250

Hod HaSharon, Petah Tikva, Ramat Gan

2027-01

Not yet open

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

NCT07441408Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

2,380

Petah Tikva

2026-12-16

Not yet open

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

NCT07861100Cardiovascular Risk, Obesity

DrugZenagamtide

Novo Nordisk A/S

Phase 3

8,500

Ashdod, Beer Yaakov, Hadera, Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva

2026-10-26

Recruiting

Stratification and Treatment in Early Psychosis Study - ENHANCE

NCT06778564Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode

University of Oxford

Phase 3

250

Hod HaSharon, Petah Tikva, Ramat Gan

2026-10-05

Recruiting

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

NCT07817875Obesity

DrugTirzepatide

Eli Lilly and Company

Phase 3

150

Beer Jacob, Beersheba, Haifa, Jerusalem, Petah Tikva

2026-09-25

Recruiting

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT07623161Myelofibrosis, Anemia

DrugElritercept

Takeda

Phase 3

324

Haifa, Tel Aviv, Jerusalem, Petah Tikva

2026-09-10

Recruiting

A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

NCT07665450Multiple Myeloma

DrugsRamantamig·Bortezomib·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,000

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2026-09-09

Recruiting

A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

NCT07630714Systemic Lupus Erythematosus

AstraZeneca

Phase 2

Haifa, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2026-08-31

Recruiting

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

NCT07776509Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2

DrugLenbelintide

AstraZeneca

Phase 3

500

Holon, Jerusalem, Kfar Saba, Petah Tikva, Tel Aviv

2026-08-24

Recruiting

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

NCT07737743Sjögren's Disease

DrugDDY391

Novartis Pharmaceuticals

Phase 2

344

Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2026-08-24

Recruiting

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

NCT07619131Hypercholesterolaemia

DrugsLaroprovstat·Rosuvastatin 2·Rosuvastatin

AstraZeneca

Phase 3

600

Haifa, Jerusalem, Kfar Saba, Petah Tikva

2026-08-12

Recruiting

Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus

NCT06593392Pruritus, Chronic Kidney Diseases

Vifor Fresenius Medical Care Renal Pharma

Phase 2

Jerusalem, Petah Tikva

2026-08-04

Not yet open

Adapted Visual Safety Plan for Autistic Youth (VSP-AY) to Address Self-harm, Suicidal Ideation, and Suicide Behaviors

NCT07333014Autism Spectrum Disorder, Suicidal Ideation, Suicidal Behavior, Self-Injurious Behavior

College of Management Academic Studies

Not applicable

Petah Tikva

2026-07-30

Recruiting

Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)

DrugsFasenra·Benralizumab

AstraZeneca

Phase 3

230

Haifa, Holon, Petah Tikva

2026-07-24

Recruiting

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

NCT07481981Pulmonary Arterial Hypertension

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 3

344

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2026-07-21

Recruiting

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

NCT07630974Malignant Neoplasm

DrugIfinatamab Deruxtecan

Merck Sharp & Dohme LLC

Phase 1/2

134

Haifa, Petah Tikva, Ramat Gan

2026-07-06

Recruiting

Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery

NCT07362992Cesarean Delivery, Postpartum Hemorrhage (PPH), Intraoperative Blood Loss, Hemostasis

DrugTranexamic Acid

Wolfson Medical Center

Early Phase 1

112

Holon, Kfar Saba, Petah Tikva, Rehovot

2026-07-01

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

NCT07581002Acute Myeloid Leukemia

DrugsPivekimab Sunirine·Azacitidine·Venetoclax

AbbVie

Phase 2/3

660

Petah Tikva, Tel Aviv, Haifa, Jerusalem

2026-06-30

Recruiting

Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

NCT07600749Malignant Neoplasm

Merck Sharp & Dohme LLC

Phase 1

120

Haifa, Petah Tikva

2026-06-18

Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658Idiopathic Pulmonary Fibrosis (IPF)

AstraZeneca

Phase 2

359

Ashkelon, Jerusalem, Kfar Saba, Petah Tikva, Rehovot

2026-06-11

Recruiting

1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection (TURBT) for Large Bladder Tumors

NCT07898033NMIBC, TCC

dmitry enikeev

Phase 3

136

Petah Tikva

2026-06-08

Not yet open

Advanced Symptom Palliation Through Integrated Relief Engagement

NCT07518797Cancer, Symptom, Quality of Life, AI (Artificial Intelligence)

Tzeela Cohen

Not applicable

Petah Tikva

2026-06-01

Not yet open

Brief Crisis Therapy for Suicidal Children and Adolescents

NCT07627243Suicidal Ideation, Suicidal Behavior

Tel Aviv University

Not applicable

120

Petah Tikva

2026-06

Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

700

Ashdod, Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2026-05-31

Recruiting

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07577856Colitis, Ulcerative

DrugsJNJ-78934804·Tremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

644

Ashdod, Haifa, Holon/Tel Aviv, Kefar Sava, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2026-05-23

Recruiting

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

NCT07577843Crohn Disease

DrugsJNJ-78934804·Tremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

460

Ashdod, Haifa, Holon/Tel Aviv, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2026-05-22

Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939HER2-positive Breast Cancer

DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine

Hoffmann-La Roche

Phase 2/3

650

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2026-05-21

Recruiting

A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex

NCT06087536Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia

Omnix Medical Ltd

Phase 2

Ashdod, Be’er Ya‘aqov, Holon, Petah Tikva, Ramat Gan, Rishon LeZiyyon

2026-05-14

Recruiting

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma

DrugsPF-08634404·Nivolumab

Pfizer

Phase 2/3

840

Petah Tikva, Ramat Gan, Tel Aviv

2026-05-14

Active, closed

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan

2026-05-11

Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110Metastatic Castration-resistant Prostate Cancer

DrugsDeutenzalutamide·Xofigo·FPI-2265·Cabazitaxel

AstraZeneca

Phase 3

670

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2026-05-04

Recruiting

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Phase 3

876

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2026-05-04

Recruiting

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

NCT07483099Crohn Disease

DrugsLY4395089·Mirikizumab

Eli Lilly and Company

Phase 2

Ashdod, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tsrifin

2026-05-04

Recruiting

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

NCT07483073Colitis, Ulcerative, Crohn Disease

DrugsLY4395089·Mirikizumab

Eli Lilly and Company

Phase 2

Ashdod, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tsrifin

2026-05-04

Not yet open

Use of Nitrous Oxide for Pain and Anxiety Management During Cervical Cerclage Removal

NCT07491874Preterm Delivery, Cervical Cerclage, Cervical Insufficiency

DrugNitrous oxide

Kaplan Medical Center

Not applicable

Rehovot, Holon, Kfar Saba, Petah Tikva

2026-05-01

Active, closed

Early (Postoperative Day 3) Versus Standard (Postoperative Day 6) Urethral Catheter Removal After Living Donor Kidney Transplantation

NCT07681843Catheter-Associated Urinary Tract Infections (CAUTIs), Kidney Transplantation

Fahim Kanani

Not applicable

172

Petah Tikva

2026-05-01

Recruiting

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

NCT07419295Bladder Cancer

DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

590

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tsrifin

2026-04-23

Recruiting

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

NCT07546500Ovarian Cancer

DrugAzenosertib

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 3

420

Ashdod, Haifa, Holon, Jerusalem, Nahariya, Petah Tikva, Safed, Tel Aviv

2026-04-17

Recruiting

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

NCT07249905Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma, PMBCL

ModeX Therapeutics, An OPKO Health Company

Phase 1/2

180

Haifa, Jerusalem, Petah Tikva, Tel Aviv

2026-04-13

Recruiting

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

NCT07489495Carcinoma, Renal Cell

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 3

758

Haifa, Kfar Saba, Petah Tikva, Ramat Gan

2026-04-09

Recruiting

A Gaucher Disease Gene Therapy Trial With FLT201

NCT07223944Gaucher Disease Type 1

Spur Therapeutics

Phase 3

Jerusalem, Petah Tikva

2026-04-07

Not yet open

Personalized Cooking and Nutrition Guidance and Physical Activities Program to Reduce Muscle Loss in Advanced Cancer

NCT07466862Cancer, Sarcopenia, Muscle Mass Loss

Gali Perel

Not applicable

200

Petah Tikva

2026-04

Recruiting

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration

DrugsTiespectus·Eylea·Aflibercept

EyeBiotech Ltd.

Phase 2/3

960

Ashkelon, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tsrifin

2026-03-27

Recruiting

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms

DrugsBelzutifan·Cabozantinib·Lenvatinib·Nivolumab

Merck Sharp & Dohme LLC

Phase 3

450

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2026-03-23

Recruiting

Long-Term Outcomes of Teplizumab in Routine Clinical Care

NCT07360080Type 1 Diabetes

DrugTeplizumab

Sanofi

Observational

1,000

Petah Tikva, Ramat Gan

2026-03-19

Active, closed

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449936Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)

DrugsEYP-1901·Aflibercept

EyePoint Pharmaceuticals, Inc.

Phase 3

240

Be’er Ya‘aqov, Haifa, Kfar Saba, Petah Tikva, Rehovot, Tel Aviv

2026-02-16

Recruiting

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

NCT07232602Bladder Cancer

DrugsMK-3120·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

Haifa, Petah Tikva

2026-02-09

Active, closed

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07266441Multiple Myeloma

DrugRamantamig

Janssen Research & Development, LLC

Phase 2

168

Afula, Ashdod, Hadera, Jerusalem, Petah Tikva, Tel Aviv

2026-02-08

Recruiting

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07222332Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

300

Beer Yaacov, Beersheba, Haifa, Herzliya, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2026-02-05

Recruiting

Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.

NCT07226089ISS, SGA

DrugSomatrogon

Rabin Medical Center

Phase 3

254

Petah Tikva, Jerusalem, Bear Sheva, Ramat Gan, Rishon LeZiyyon, Tel Aviv

2026-02-01

By invitation

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

NCT07286006Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

372

Beersheba, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2026-01-26

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT07216703Cervical Cancer

DrugsMvasi·Paraplatin·Sacituzumab tirumotecan·Avastin

Merck Sharp & Dohme LLC

Phase 3

1,023

Hadera, Haifa, Jerusalem, Petah Tikva, Tel Aviv

2026-01-19

Recruiting

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222137Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

150

Beer Yaacov, Beersheba, Haifa, Herzliya, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2026-01-12

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

NCT07284459Idiopathic Pulmonary Fibrosis

Contineum Therapeutics

Phase 2

324

Be’er Ya‘aqov, Kafr Saba, Petah Tikva, Ramat Gan, Rehovot, Hadera, Jerusalem, Ashdod

2026-01-08

Recruiting

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

NCT07253285Overweight, Obesity

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

460

Haifa, Jerusalem, Petah Tikva, Tsrifin

2026-01-08

Recruiting

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380Pulmonary Hypertension, Interstitial Lung Disease

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 3

344

Petah Tikva, Jerusalem, Haifa, Tel Aviv

2026-01-07

Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsPF-08634404·Pembrolizumab

Pfizer

Phase 3

1,410

Petah Tikva, Ramat Gan, Tsrifin, Jerusalem, Tel Aviv

2026-01-06

Recruiting

Urine Output Response to Fluid and Diuretic Therapy in Cardiac ICU Patients Monitored With FIZE kUO®

NCT07022314AKI - Acute Kidney Injury, Cardiac Surgery, Fluid Therapy, Hemodynamic Instability

FIZE Medical ltd

Observational

Petah Tikva

2026-01-01

Recruiting

Transversus Abdominis Plane Block Versus Wound Infiltration for Pulmonary Function Preservation Following Laparoscopic Living Donor Nephrectomy

NCT06837909Postoperative Pain

Rabin Medical Center

Not applicable

Petah Tikva

2026-01-01

Not yet open

Time in rANge vs. Time in nOrmal Glycemia for Better Glycemic Control

NCT07376850Diabetes, Diabetes (DM), Diabetes Type 1

University Hospital, Motol

Not applicable

120

Petah Tikva

2026-01

Recruiting

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

NCT07247110Malignant Neoplasm

DrugsCetuximab·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1

250

Haifa, Petah Tikva, Ramat Gan

2025-12-16

Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site

DrugsPF-08634404·Avastin·Bevacizumab

Pfizer

Phase 3

800

Petah Tikva, Ramat Gan, Haifa, Jerusalem, Tel Aviv

2025-12-11

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07155187Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib

AbbVie

Phase 2/3

490

Kefar Sava, Petah Tikva, Tsrifin, Ramat Gan, Haifa

2025-12-10

Recruiting

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

NCT07222488Bladder Cancer, Urinary Bladder Neoplasms

DrugMK-3120

Merck Sharp & Dohme LLC

Phase 1/2

Petah Tikva

2025-12-09

Recruiting

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT07230691Carcinoma, Non-Small-Cell Lung

Janssen Research & Development, LLC

Observational

380

Petah Tikva, Ramat Gan, Tel Aviv

2025-12-03

Recruiting

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

NCT07276724Severe Asthma

DrugGB-0895

Generate Biomedicines

Phase 3

786

Haifa, Beersheba, Petah Tikva, Jerusalem, Tel Aviv, Kfar Saba, Ramat Gan

2025-12-03

Recruiting

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

NCT07116031Chronic Graft Versus Host Disease

DrugBelumosudil

Sanofi

Phase 2

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-12-02

Recruiting

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease

DrugOrforglipron

Eli Lilly and Company

Phase 3

7,140

Ashdod, Ashkelon, Beersheba, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva

2025-12-01

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

NCT07196644Solid Tumors Harboring MET Amplification

DrugTelisotuzumab Adizutecan

AbbVie

Phase 2

100

Petah Tikva, Ramat Gan, Tel Aviv, Jerusalem

2025-12-01

Recruiting

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

NCT06994845Primary Immunoglobulin A Nephropathy (IgAN)

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Beersheba, Haifa, Jerusalem, Petah Tikva

2025-11-27

Recruiting

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT06930625Acromegaly

Debiopharm International SA

Phase 3

119

Haifa, Petah Tikva, Tel Aviv

2025-11-26

Recruiting

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

NCT07211958Acute Myeloid Leukemias

DrugRevumenib

Syndax Pharmaceuticals

Phase 3

468

Petah Tikva, Jerusalem, Tel Aviv, Tel HaShomer, Haifa

2025-11-25

Recruiting

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

NCT07206225Non-muscle Invasive Bladder Cancer

DrugSasanlimab

Pfizer

Phase 1

294

Petah Tikva, Ramat Gan, Jerusalem, Haifa

2025-11-06

Recruiting

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065Neovascular Age-related Macular Degeneration

DrugSurabgene Lomparvovec

AbbVie

Phase 3

561

Holon, Petah Tikva, Rehovot, Tsrifin, Ramat Gan, Tel Aviv, Haifa, Jerusalem

2025-11-05

Recruiting

Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock

NCT07293923Cardiogenic Shock, Heart Failure, Acute Myocardial Infarction (AMI)

Magenta Medical Ltd.

Not applicable

Be’er Ya‘aqov, Haifa, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2025-11-05

Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Ribociclib·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

1,000

Kfar Saba, Petah Tikva, Jerusalem, Ashdod

2025-11-03

Recruiting

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

NCT07223593Peripheral Arterial Disease

DrugOrforglipron

Eli Lilly and Company

Phase 3

1,205

Haifa, Jerusalem, Kfar Saba, Petah Tikva

2025-10-31

Recruiting

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

NCT07201051Bronchiectasis

DrugGSK3862995B

GlaxoSmithKline

Phase 2

363

Ashdod, Ashkelon, Beersheba, Haifa, Jerusalem, Kfar Saba, Koranit, Petah Tikva

2025-10-30

Active, closed

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121Pancreatic Ductal Adenocarcinoma

DrugsNavlimetostat·Abraxane·Nab-paclitaxel·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

470

Ramat Gan, Tsrifin, Jerusalem, Afula, Tel Aviv, Petah Tikva

2025-10-23

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

Ashkelon, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-10-15

Recruiting

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

NCT07175285Systemic Lupus Erythematosus (SLE)

Bristol-Myers Squibb

Observational

223

Kfar Saba, Ramat Gan, Haifa, Petah Tikva, Tel Aviv

2025-10-08

Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

DrugPonsegromab

Pfizer

Phase 2/3

982

Petah Tikva, Ramat Gan, Haifa, Jerusalem, Tel Aviv

2025-10-03

Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722Crohn Disease

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 2/3

1,092

Afula, Ashdod, Be’er Ya‘aqov, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan

2025-10-03

Recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

NCT05745714Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory

DrugsRuxolitinib·Cytarabine·Venetoclax·Dexamethasone

Princess Maxima Center for Pediatric Oncology

Phase 1/2

Petah Tikva, Ramat Gan

2025-10-01

By invitation

A Long-Term Study of Navenibart in Participants With Hereditary Angioedema

NCT07204938Hereditary Angioedema (HAE)

DrugNavenibart

Astria Therapeutics, Inc.

Phase 3

145

Ashkelon, Haifa, Petah Tikva

2025-10-01

Recruiting

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

NCT05751044Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory

DrugsDasatinib·Cytarabine·Venetoclax·Dexamethasone

Princess Maxima Center for Pediatric Oncology

Phase 1/2

Petah Tikva, Ramat Gan

2025-10-01

Recruiting

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931Crohn's Disease

DrugDuvakitug

Sanofi

Phase 3

980

Afula, Ashkelon, Beersheba, Jerusalem, Nahariya, Petah Tikva, Tel Aviv

2025-10-01

Active, closed

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748Colitis, Ulcerative

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

896

Afula, Ashdod, Be’er Ya‘aqov, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan

2025-10-01

Recruiting

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

NCT07106762Urothelial Cancer

DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

470

Petah Tikva, Tsrifin, Jerusalem, Haifa

2025-09-30

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

Petah Tikva, Ramat Gan, Tsrifin, Jerusalem, Tel Aviv

2025-09-29

Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

1,000

Petah Tikva, Ramat Gan, Tsrifin, Jerusalem, Haifa, Tel Aviv

2025-09-28

Recruiting

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

NCT07190196Immunoglobulin G4 Related Disease

DrugRilzabrutinib

Sanofi

Phase 3

124

Petah Tikva, Tel Aviv, Kefar Sava, Nahariya

2025-09-26

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

NCT07190222Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Ashkelon, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2025-09-17

Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868Breast Neoplasms

DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

600

Petah Tikva, Ramat Gan, Jerusalem, Hadera, Haifa

2025-09-11

Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965Non-Muscle Invasive Bladder Neoplasms

DrugsErdafitinib·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

220

Haifa, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2025-09-10

Recruiting

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsTacabrutideg·Pirtobrutinib

BeOne Medicines

Phase 3

500

Haifa, Jerusalem, KfarSava, Petah Tikva, Ramat Gan, Tel Aviv

2025-09-04

Not yet open

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

NCT06951399NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IV Without EGFR/ALK Mutation, NSCLC Adenocarcinoma

DrugsKeytruda·Pembrolizumab

Rabin Medical Center

Phase 2

Petah Tikva

2025-09-01

Active, closed

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin

Amgen

Phase 3

350

Kfar Saba, Petah Tikva

2025-08-18

Recruiting

Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial.

NCT07208240High Risk Prostate Cancer

Rabin Medical Center

Phase 1/2

Petah Tikva

2025-08-12

Recruiting

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

NCT06774131Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma

UroGen Pharma Ltd.

Phase 3

Kefar Sava, Ramat Gan, Haifa, Petah Tikva, Tsrifin

2025-08-06

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2025-08-06

Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803Prostate Cancer

DrugsPrednisolone/prednisone·Saruparib·Abiraterone

AstraZeneca

Phase 3

700

Afula, Beersheba, Hadera, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva

2025-08-06

Recruiting

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965Breast Cancer

DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant

Pfizer

Phase 3

400

Petah Tikva, Ramat Gan, Jerusalem, Haifa, Tel Aviv

2025-08-05

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07005102Non-Squamous Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib·Pemetrexed·Cisplatin

AbbVie

Phase 2/3

854

Petah Tikva, Ramat Gan, Haifa

2025-08-03

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

NCT07024784Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)

DrugsIMGN151·Olaparib·Bevacizumab·Carboplatin

AbbVie

Phase 2

377

Petah Tikva, Ramat Gan, Tel Aviv, Haifa, Jerusalem

2025-07-30

Recruiting

Harmony TPV EMEA PMS

NCT06906926Severe Pulmonary Valve Regurgitation

Medtronic Cardiovascular

Not applicable

Petah Tikva

2025-07-30

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone

AbbVie

Phase 1/2

325

Petah Tikva, Ramat Gan, Tel Aviv, Haifa, Jerusalem

2025-07-23

Recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsSigvotatug vedotin·Pembrolizumab

Pfizer

Phase 3

714

Jerusalem, Petah Tikva

2025-07-23

Recruiting

Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.

NCT06940388Locally Advanced Rectal Cancer (LARC)

DrugTislelizumab

brenner baruch

Phase 2

134

Petah Tikva

2025-07-23

Recruiting

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

NCT07049926Renal Cell Carcinoma

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 1/2

140

Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2025-07-20

Recruiting

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

NCT06929273Bipolar Disorder Type I With Mania

DrugsValproate·Lamotrigine·Lithium·KarXT

Bristol-Myers Squibb

Phase 3

450

Hod HaSharon, Ness Ziona, Petah Tikva, Ramat Gan, Beersheba, Ashkelon, Jerusalem

2025-07-18

Active, closed

Safety and Performance, and Dose, of OsteoAdapt DE in Localized Alveolar Ridge Augmentations

NCT07078331Tooth Extraction Site Healing, Ridge Augmentation, Bone Graft

Theradaptive, Inc

Phase 1/2

Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer

2025-07-17

Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma

DrugsLeucovorin/levofolinate calcium·Bevacizumab biosimilar·Calderasib·Mvasi

Merck Sharp & Dohme LLC

Phase 3

477

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-07-16

Recruiting

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

NCT06863272Castration-Resistant Prostatic Cancer, Metastasis

DrugsOpevesostat·Ifinatamab Deruxtecan·Abiraterone·Enzalutamide

Merck Sharp & Dohme LLC

Phase 1/2

360

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-07-03

Active, closed

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07047118Prostatic Cancer, Castration-Resistant

DrugsLuxdegalutamide·Lu-PSMA

Novartis Pharmaceuticals

Phase 2

138

Afula, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan

2025-07-03

Recruiting

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903Transthyretin Amyloidosis With Cardiomyopathy

DrugNucresiran

Alnylam Pharmaceuticals

Phase 3

1,750

Be’er Ya‘aqov, Haifa, Jerusalem, Petah Tikva

2025-07-02

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

NCT06892522Multiple Myeloma

DrugsMezigdomide·Etentamig·Iberdomide·Carfilzomib

AbbVie

Phase 1/2

602

Petah Tikva, Beersheba, Ramat Gan, Haifa, Jerusalem

2025-06-30

Recruiting

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086Ulcerative Colitis, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

350

Ashdod, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2025-06-26

Recruiting

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099Crohn's Disease, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

290

Ashdod, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2025-06-26

Recruiting

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT06961214Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

961

Ashkelon, Beer-Yaakov, Beersheba, Hadera, Haifa, Jerusalem, Kfar Saba, Petah Tikva

2025-06-23

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT07018323Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

210

Ramat Gan, Haifa, Nahariya, Tzfat, Beersheba, Jerusalem, Kfar Saba, Petah Tikva

2025-06-19

Active, closed

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744Ulcerative Colitis

DrugsRisankizumab·Vedolizumab

AbbVie

Phase 3

573

Petah Tikva, Tsrifin, Ashdod, Beersheba, Ramat Gan, Tel Aviv, Haifa

2025-06-17

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

NCT06951711Bipolar Disorder Type I With Mania or Mania With Mixed Features

DrugKarXT

Bristol-Myers Squibb

Phase 3

274

Hod HaSharon, Ness Ziona, Petah Tikva, Ramat Gan, Beersheba, Jerusalem

2025-06-13

Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568Endometrial Cancer

DrugsDoxorubicin·Docetaxel·Paclitaxel

BioNTech SE

Phase 3

480

Hadera, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-06-10

Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,755

Haifa, Jerusalem, Petah Tikva, Tel Aviv

2025-06-09

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

Beer Yaakov, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-06-04

Recruiting

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627Venous Leg Ulcer (VLU)

DrugEscharEx

MediWound Ltd

Phase 3

216

Petah Tikva, Nahariya, Beersheba, Be’er Ya‘aqov, Ramat Gan, Rehovot

2025-06-01

Not yet open

Assessing the Safety, Performance, and User Experience of the Tandem Mobi Automated Insulin Delivery System Among Young Competitive Athletes in Real-world Settings.

NCT06979635Type 1 Diabetes

Rabin Medical Center

Not applicable

Petah Tikva

2025-06

Active, closed

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

NCT06961006Malignant Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

160

Afula, Jerusalem, Petah Tikva, Ramat Gan

2025-05-29

Recruiting

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

NCT06780098Lung Neoplasm

DrugsR-DXd·Ifinatamab Deruxtecan·Taxotere·Docetaxel

Merck Sharp & Dohme LLC

Phase 2

144

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2025-05-28

Recruiting

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301Advanced Melanoma

DrugsEIK1001·Keytruda·Pembrolizumab

Eikon Therapeutics

Phase 2/3

740

Beersheba, Petah Tikva, Ramat Gan, Tel Aviv

2025-05-22

Active, closed

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

NCT06780085Carcinoma, Non-Small-Cell Lung

DrugsR-DXd·Ifinatamab Deruxtecan

Merck Sharp & Dohme LLC

Phase 2

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2025-05-13

Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737Prostate Cancer, Prostatic Neoplasms

DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

1,440

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2025-05-13

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

130

Haifa, Petah Tikva, Ramat Gan

2025-05-12

Recruiting

Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Injections

NCT06966427Type 1 Diabetes, Type 2 Diabetes

Rabin Medical Center

Not applicable

Petah Tikva

2025-05-08

Recruiting

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT06499285Myelodysplastic Syndromes

DrugElritercept

Takeda

Phase 3

225

Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-05-06

Recruiting

Safety of HRX215 in Patients After Minor and Major Liver Resection

NCT06638502Liver Resection, Colorectal Carcinoma Liver Metastases

HepaRegeniX GmbH

Phase 1/2

Petah Tikva, Ramat Gan, Tel Aviv

2025-05-06

Active, closed

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06914895Type 1 Diabetes, Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

905

Beer Yaacov, Beersheba, Haifa, Herzliya, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-04-25

Recruiting

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

NCT06820463Metastatic Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Panitumumab·Fluorouracil·Leucovorin

AbbVie

Phase 2

390

Petah Tikva, Tel Aviv, Haifa, Jerusalem

2025-04-24

Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310Carcinoma, Non-Small-Cell Lung

DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin

Mirati Therapeutics Inc.

Phase 3

630

Petah Tikva, Ramat Gan, Tsrifin, Jerusalem, Haifa

2025-04-24

Recruiting

Lung Ultrasound for Guiding Antibiotic Use in Pediatric Pneumonia

NCT06921993Pneumonia Childhood, Pneumonia, Lung Ultrasound, Antibiotic Stewardship

Meyer Children's Hospital IRCCS

Not applicable

659

Petah Tikva

2025-04-24

Recruiting

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

NCT06880770Severe Hypertriglyceridemia

DrugPlozasiran

Arrowhead Pharmaceuticals

Phase 3

288

Ashkelon, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2025-04-24

Recruiting

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

NCT06512883Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)

DrugsFasenra·Benralizumab

AstraZeneca

Phase 3

Petah Tikva

2025-04-17

Recruiting

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

NCT06843447Ovarian Cancer Recurrent

DrugsMK-2010·R-DXd·Zirabev·Pegylated liposomal doxorubicin

Merck Sharp & Dohme LLC

Phase 1/2

605

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2025-04-15

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

NCT06858813Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer

DrugLenvatinib

AbbVie

Phase 1

232

Petah Tikva, Haifa, Jerusalem

2025-04-14

Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884Lymphoma, Large B-Cell, Diffuse

DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 2

594

Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Safed, Tel Aviv

2025-04-11

Not yet open

Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet (KD) Combined With Immunotherapy in Adults With Advanced Melanoma, cSCC, or RCC.

NCT06896552Cancer, Immunotherapy, Ketogenic Diet

Rabin Medical Center

Phase 1/2

Petah Tikva

2025-04

Not yet open

Iron Deficiency in Pediatric Celiac Disease: Diet vs. Iron Supplementation Trial

NCT06921343Celiac Disease in Children, Iron Deficiency

Kaplan Medical Center

Not applicable

150

Ashdod, Haifa, Kfar Saba, Petah Tikva, Rehovot

2025-04

Recruiting

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

NCT06731907Non-small Cell Lung Cancer

DrugsPatritumab deruxtecan·Abraxane·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 2

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2025-03-30

Recruiting

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

NCT06830759Diffuse Large B-cell Lymphoma, Follicular Lymphoma

AbbVie

Observational

700

Tel Aviv, Jerusalem, Petah Tikva

2025-03-28

Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT06818643Advanced Solid Tumors, Malignant Neoplasm

DrugMK-3120

Merck Sharp & Dohme LLC

Phase 1/2

270

Haifa, Petah Tikva, Ramat Gan

2025-03-25

Active, closed

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823Hereditary Angioedema (HAE)

DrugNavenibart

Astria Therapeutics, Inc.

Phase 3

157

Ashkelon, Haifa, Petah Tikva, Tel Aviv

2025-03-20

Recruiting

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

NCT06819007Ovarian Cancer

DrugsTrastuzumab deruxtecan·Bevacizumab

Daiichi Sankyo

Phase 3

582

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Tel Aviv, Tel HaShomer

2025-03-19

Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354Triple Negative Breast Neoplasms

DrugsAbraxane·Paraplatin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,000

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-03-16

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

Beersheba, Be’er Ya‘aqov, Haifa, Herzelia, Holon, Jerusalem, Petah Tikva, Ramat Gan

2025-03-14

Active, closed

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485Metastatic Castration-resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide·Docetaxel

Celgene

Phase 3

960

Kfar Saba, Petah Tikva, Ramat Gan, Tsrifin, Haifa

2025-03-13

Recruiting

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

5,000

Afula, Ashdod, Be’er Ya‘aqov, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva

2025-03-03

Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

NCT06780137Small Cell Lung Cancer

DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab

Merck Sharp & Dohme LLC

Phase 1/2

327

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2025-02-27

Recruiting

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670Prostate Cancer

DrugAAA817

Novartis Pharmaceuticals

Phase 2/3

443

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2025-02-27

Recruiting

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

NCT06686394Breast Neoplasms, Breast Cancer

DrugsOgivri·Herzuma·Patritumab deruxtecan·Tucatinib

Merck Sharp & Dohme LLC

Phase 1/2

181

Haifa, Petah Tikva, Ramat Gan

2025-02-26

Active, closed

Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI

NCT06811805AKI - Acute Kidney Injury, Cardiac Surgery Associated - Acute Kidney Injury

CardioRenal Systems, Inc.

Not applicable

300

Haifa, Petah Tikva

2025-02-23

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834347Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

231

Haifa, Kefar Sava, Petah Tikva, Tel Aviv

2025-02-12

Active, closed

REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure

NCT06557798Aortic Valve Stenosis

The Leeds Teaching Hospitals NHS Trust

Observational

550

Holon, Jerusalem, Petah Tikva

2025-02-04

Active, closed

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

NCT06556563Glioblastoma

DrugsTemozolomide·Keytruda·Pembrolizumab

NovoCure GmbH

Phase 3

741

Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2025-02-03

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Beersheba, Jerusalem, Petah Tikva, Tel Aviv

2025-01-28

Recruiting

Pictorial Fit-Frail Scale in Adults Admitted to the ICU in a Tertiary Center- an Observational Prospective Study

NCT06729502Frail

Rabin Medical Center

Observational

1,350

Petah Tikva

2025-01-26

Recruiting

The Effect of Superficial Parasternal Intercostal Plane Block on Pulmonary Function Tests After Cardiac Surgery

NCT05999721Postoperative Pain, Pulmonary Function Tests

Shai Fein

Not applicable

100

Petah Tikva

2025-01-25

Active, closed

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

NCT06632951Urothelial Carcinoma

DrugsLivmoniplimab·Budigalimab·Docetaxel·Gemcitabine

AbbVie

Phase 2

150

Kfar Saba, Ramat Gan, Tel Aviv, Haifa, Petah Tikva

2025-01-20

Recruiting

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06568939Non-Small Cell Lung Cancer, c-MET

DrugTelisotuzumab vedotin

AbbVie

Phase 2

150

Kefar Sava, Petah Tikva, Ramat Gan, Haifa, Jerusalem

2025-01-20

Recruiting

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

NCT06759649Neoplasm, Cancer, Malignant Tumors

DrugZimberelimab

Compugen Ltd

Phase 1

200

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2025-01-07

Active, closed

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637Breast Cancer

DrugsAtirmociclib·Ribociclib·Abemaciclib·Palbociclib

Pfizer

Phase 3

1,035

Petah Tikva, Ramat Gan, Jerusalem, Haifa, Tel Aviv

2025-01-06

Recruiting

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

NCT06227910Crohn's Disease

DrugsVedolizumab·Upadacitinib

Takeda

Phase 3

396

Beersheba, Haifa, Kfar Saba, Petah Tikva, Tel Aviv

2025-01-02

Recruiting

Early Transcatheter Mitral Valve Repair After Myocardial Infarction

NCT06282042Acute Mitral Regurgitation

Fundación para la Investigación Biosanitaria del Principado de Asturias

Not applicable

250

Afula, Jerusalem, Petah Tikva, Ramat Gan

2024-12-24

Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma

DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 3

520

Beersheba, Jerusalem, Koranit, Petah Tikva, Tel Aviv

2024-12-16

Recruiting

A National Screening Program for Islet Autoantibodies Among First-degree Relatives of T1D Patients

NCT06665815Type 1 Diabetes, Autoantibodies Screening

Rabin Medical Center

Observational

20,000

Petah Tikva

2024-12-15

Recruiting

Carb Counting vs. Simplified Qualitative Meal-Size Estimation

NCT06687434Type 1 Diabetes Mellitus

Rabin Medical Center

Not applicable

120

Petah Tikva

2024-12-15

Active, closed

Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults

NCT06547151Hypoparathyroidism

Amorphical Ltd.

Phase 2

Ashdod, Haifa, Jerusalem, Petah Tikva, Ashkelon, Beersheba, Ramat Gan, Rehovot

2024-12-15

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Beer Yaakov, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2024-12-12

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Ashkelon, Haifa, Har Poriyya, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2024-12-04

Active, closed

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

NCT06683742Wet Age Related Macular Degeneration, wAMD

DrugsEYP-1901·Aflibercept

EyePoint Pharmaceuticals, Inc.

Phase 3

400

Be’er Ya‘aqov, Haifa, Kfar Saba, Petah Tikva, Rehovot, Tel Aviv

2024-11-27

Recruiting

A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis

NCT06443502Pouchitis

DrugVedolizumab

Takeda

Phase 3

Jerusalem, Petah Tikva

2024-11-19

Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

NCT06672549Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

125

Beer Yaacov, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan

2024-11-18

Recruiting

Vsling™ I: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure

NCT06851949Heart Failure With Reduced Ejection Fraction

Cardiac Success

Phase 2

Be’er Ya‘aqov, Haifa, Jerusalem, Petah Tikva, Poria – Neve Oved

2024-11-15

Recruiting

Namodenoson Treatment of Advanced Pancreatic Cancer

NCT06387342Pancreatic Adenocarcinoma, Pancreatic Cancer

DrugNamodenoson

Can-Fite BioPharma

Phase 2

Petah Tikva

2024-11-10

Active, closed

A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy

NCT06713135Duchenne Muscular Dystrophy

DrugVamorolone

Santhera Pharmaceuticals

Phase 4

Petah Tikva

2024-11-10

Active, closed

A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

NCT06614192Metastatic Colorectal Cancer

DrugTelisotuzumab Adizutecan

AbbVie

Phase 2

Petah Tikva, Haifa, Jerusalem, Ramat Gan, Tel Aviv

2024-11-08

Active, closed

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319Asthma

DrugsBudesonide/Formoterol·Lunsekimig

Sanofi

Phase 2

556

Haifa, Jerusalem, Petah Tikva, Rehovot, Tel Aviv

2024-11-07

Recruiting

Histiocytosis and Inflammatory Manifestations in Patients with H Syndrome

NCT06742073H Syndrome

Rabin Medical Center

Observational

120

Petah Tikva

2024-11-01

Active, closed

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193Parkinson Disease

Denali Therapeutics Inc.

Phase 2

Petah Tikva, Ramat Gan, Tel Aviv

2024-10-24

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Beer Yaakov, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2024-10-18

Active, closed

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

768

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2024-10-04

Recruiting

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

2,150

Petah Tikva, Ramat Gan, Haifa, Afula, Nahariya, Jerusalem, Tel Aviv

2024-10-04

By invitation

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

NCT06609239Asthma

DrugLunsekimig

Sanofi

Phase 2

900

Ashkelon, Haifa, Jerusalem, Petah Tikva, Rehovot, Tel Aviv

2024-09-30

Recruiting

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787Alzheimer Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

406

Jerusalem, Ashkelon, Petah Tikva, Ramat Gan

2024-09-26

Recruiting

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

NCT06462235Gram-negative Bacterial Infection

Pfizer

Phase 2

Petah Tikva, Haifa

2024-09-25

Active, closed

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

DrugSotagliflozin

Lexicon Pharmaceuticals

Phase 3

500

Be’er Ya‘aqov, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2024-09-24

Recruiting

Safety and Effectiveness of eGERD Device to Reduce Gastroesophageal Reflux Disease (GERD) Symptoms

NCT06613438GERD (Gastroesophageal Reflux Disease)

Gerd Care Medical Ltd

Not applicable

Afula, Haifa, Petah Tikva, Tel Aviv

2024-09-15

Active, closed

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06550076Plaque Psoriasis

DrugZasocitinib

Takeda

Phase 3

2,099

Petah Tikva, Ramat Gan

2024-09-04

Active, closed

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

NCT06557772Coeliac Disease, Celiac Disease

DrugAmlitelimab

Sanofi

Phase 2

229

Afula, Beersheba, Jerusalem, Petah Tikva, Ramat HaSharon, Rehovot

2024-08-29

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

699

Petah Tikva, Afula, Jerusalem, Beersheba, Ramat Gan

2024-08-19

Active, closed

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

NCT05861999Muscular Atrophy, Spinal

DrugRisdiplam

Hoffmann-La Roche

Phase 4

Beersheba, Petah Tikva, Tel Aviv

2024-08-14

Recruiting

Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System

NCT06360380Chronic Heart Failure, CKD Stage 3

AquaPass Medical Ltd.

Not applicable

Haifa, Petah Tikva

2024-08-12

Active, closed

A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045Diabetic Macular Edema (DME)

DrugsRemigromig·Lucentis·Ranibizumab

EyeBiotech Ltd.

Phase 2/3

984

Be’er Ya‘aqov, Haifa, Jerusalem, Petah Tikva, Rehovot, Tel Aviv

2024-08-07

Active, closed

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

NCT06492291Hypercholesterolemia

DrugsEnlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

3,000

Hadera, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Sakhnin, Tsrifin

2024-08-05

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2024-08-01

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

Haifa, Jerusalem, Petah Tikva, Ramat Gan, HaMerkaz, Tel Aviv

2024-07-19

Active, closed

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

NCT06483334Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma

DrugsEnfortumab Vedotin·Sacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

Haifa, Petah Tikva, Ramat Gan

2024-07-17

Active, closed

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346Essential Thrombocythemia

DrugsBomedemstat·Hydroxyurea

Merck Sharp & Dohme LLC

Phase 3

300

Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2024-07-16

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Petah Tikva, Afula, Nahariya, Ramat Gan, Tel Aviv, Haifa, Jerusalem

2024-06-27

Active, closed

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

10,000

Beer Yaakov, Hadera, Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Rehovot

2024-06-25

Recruiting

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis

NCT06429176Cystic Fibrosis

SpliSense Ltd.

Phase 2

Jerusalem, Petah Tikva

2024-06-24

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Beersheba, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2024-06-24

Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143Non-small Cell Lung Cancer, NSCLC

DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

851

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2024-06-10

Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297Neutropenia

X4 Pharmaceuticals

Phase 3

176

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2024-06-06

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Haifa, Jerusalem, Kfar Saba, Petah Tikva

2024-06-05

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Afula, Ashkelon, Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2024-06-05

Recruiting

Bio Refine for Functional Mitral Regurgitation - a Safety & Feasibility Study

NCT06583876Functional Mitral Regurgitation

Bio Refine Ltd.

Not applicable

Petah Tikva

2024-06-03

Recruiting

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

NCT06439277Obesity, Weight Gain

DrugTirzepatide

Eli Lilly and Company

Phase 3

300

Afula, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2024-06-03

Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

DrugPegozafermin

Hoffmann-La Roche

Phase 3

1,800

Afula, Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Tel Aviv, Tel HaShomer

2024-05-24

Active, closed

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386Prostatic Neoplasms, Castration-Resistant

DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere

Merck Sharp & Dohme LLC

Phase 1/2

220

Haifa, Petah Tikva, Ramat Gan

2024-05-20

Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection

Vedanta Biosciences, Inc.

Phase 3

852

Petah Tikva, Tel Aviv, Tsrifin, Haifa, Hadera, Jerusalem, Ashkelon, Tel HaShomer

2024-05-20

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Petah Tikva, Jerusalem, Ramat Gan, Tel Aviv

2024-05-19

Active, closed

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 3

1,541

Afula, Beersheba, Haifa, Jerusalem, Petah Tikva

2024-05-08

Recruiting

Stepped-Care for Suicidal Youth and Children

NCT07321171Suicidal Ideation and Behavior

Shira Barzilay

Not applicable

350

Petah Tikva

2024-05-07

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

473

Hadera, Haifa, Jerusalem, Petah Tikva, Tel Aviv

2024-05-03

Active, closed

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

DrugRetatrutide

Eli Lilly and Company

Phase 3

10,000

Ashkelon, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan, Rehovot

2024-04-30

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961End Stage Kidney Disease

DrugClazakizumab

CSL Behring

Phase 2/3

3,110

Afula, Ashkelon, Haifa, Holon, Nahariya, Petah Tikva, Ramat Gan, Rehovot

2024-04-27

Active, closed

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

NCT06408935Crohn's Disease

DrugsTremfya·Guselkumab

Janssen-Cilag Ltd.

Phase 3

120

Haifa, Holon, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2024-04-17

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

1,200

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2024-04-14

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2024-04-03

Active, closed

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376Immunoglobulin A Nephropathy, IgAN

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

584

Haifa, Jerusalem, Nazareth, Petah Tikva, Tel Aviv

2024-03-29

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

2,554

Ashkelon, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2024-03-29

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875Ulcerative Colitis

DrugsLutikizumab·Humira·Adalimumab

AbbVie

Phase 2

156

Tsrifin, Jerusalem, Beersheba, Ramat Gan, Tel Aviv, Petah Tikva

2024-03-23

By invitation

ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

NCT05932615Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder

Abbott Medical Devices

Not applicable

1,500

Jerusalem, Petah Tikva

2024-03-15

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

Hoffmann-La Roche

Phase 3

1,350

Afula, Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2024-03-13

Recruiting

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

NCT05509777Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

Beersheba, Israel, Jerusalem, Petah Tikva, Rehovot

2024-03-13

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05923073Crohn's Disease

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

120

Beersheba, Be’er Ya‘aqov, Jerusalem, Petah Tikva, Rehovot

2024-03-13

Recruiting

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414Oligometastatic Prostate Cancer (OMPC)

DrugsPiflufolastat·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

450

Beersheba, Haifa, Jerusalem, Petah Tikva, Tel Aviv

2024-03-12

Recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

NCT05646381Aortic Stenosis

DrugPelacarsen

Novartis Pharmaceuticals

Phase 2

502

Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2024-03-07

Active, closed

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

DrugLepodisiran

Eli Lilly and Company

Phase 3

17,300

Afula, Beersheba, Haifa, Holon, Jerusalem, Kfar Saba, Nahariya, Petah Tikva

2024-03-05

Active, closed

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081Early Breast Cancer

DrugsLeuprolide·Goserelin·Exemestane·Ribociclib

Novartis Pharmaceuticals

Phase 3

1,466

Beersheba, Petah Tikva, Ramat Gan, Tel Aviv

2024-02-28

Active, closed

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

NCT06012435Carcinoma, Non-Small-Cell Lung

DrugsSigvotatug vedotin·Docetaxel

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

762

Tel Aviv, Jerusalem, Kfar Saba, Petah Tikva, Rehovot

2024-02-21

Active, closed

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574Lung Cancer, Non-squamous, Non-small Cell

DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin

Boehringer Ingelheim

Phase 3

428

Haifa, Kfar Saba, Petah Tikva, Tel Aviv

2024-02-09

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575Multiple Myeloma

DrugsElotuzumab·Elranatamab·Carfilzomib·Pomalidomide

Pfizer

Phase 3

492

Petah Tikva, Ramat Gan, Jerusalem, Beersheba, Tel Aviv

2024-02-08

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744Follicular Lymphoma (FL)

DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine

Genmab

Phase 3

1,095

Kfar Saba, Petah Tikva, Afula, Jerusalem, Beersheba, Ramat Gan, Tel Aviv

2024-02-05

Active, closed

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

NCT06107426Parkinson's Disease (PD)

AbbVie

Observational

427

Jerusalem, Ramat Gan, Tel Aviv, Haifa, Petah Tikva

2024-01-24

Active, closed

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

NCT06225596Metastatic Urothelial Cancer

DrugsZelenectide pevedotin·Avelumab·Gemcitabine·Cisplatin

BicycleTx Limited

Phase 2

375

Haifa, Jerusalem, Petah Tikva

2024-01-24

Active, closed

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891Chronic Graft Versus Host Disease

DrugsBelumosudil·Prednisolone·Prednisone

Sanofi

Phase 3

260

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2024-01-23

Recruiting

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

NCT06179069SCLC

DrugsZL-1310·Atezolizumab·Carboplatin

Zai Lab (Shanghai) Co., Ltd.

Phase 1

339

Petah Tikva, Ramat Gan, Tel Aviv

2024-01-23

Active, closed

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150Multiple Myeloma

DrugsElotuzumab·Talquetamab·Velcade·Teclistamab

Janssen Research & Development, LLC

Phase 3

838

Be’er Ya‘aqov, Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2024-01-22

Active, closed

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337Metastatic Breast Cancer

DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel

DualityBio Inc.

Phase 3

541

Ashdod, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2024-01-18

Active, closed

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931Transthyretin Amyloid Cardiomyopathy

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,182

Beer Yaakov, Haifa, Jerusalem, Petah Tikva, Rehovot

2024-01-11

Recruiting

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

NCT06174987Advanced Cancer, Metastatic Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

Petah Tikva

2024-01-05

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2023-12-31

Recruiting

Prelabor Visual Biofeedback by a Self-operated Ultrasound Device

NCT06049784Obstetric Labor Complications, Obstetric Trauma

Rabin Medical Center

Not applicable

159

Petah Tikva

2023-12-31

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624Prostate Cancer Metastatic

DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone

Merck Sharp & Dohme LLC

Phase 3

1,310

Afula, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2023-12-31

Recruiting

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

DrugsOdronextamab·Lenalidomide·Rituximab

Regeneron Pharmaceuticals

Phase 3

580

Ashdod, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2023-12-28

Recruiting

Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction

NCT05992363Hydronephrosis; Obstruction, Ureter, Renal Failure, Malignancy, Ureter Obstruction

Rabin Medical Center

Not applicable

106

Petah Tikva, Ramat Gan

2023-12-20

Recruiting

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

NCT05912517Hemolytic Disease of the Fetus and Newborn

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

120

Jerusalem, Petah Tikva, Ramat Gan

2023-12-20

Active, closed

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411Vitiligo

DrugUpadacitinib

AbbVie

Phase 3

614

Petah Tikva, Jerusalem, Ramat Gan, Tel Aviv, Haifa

2023-12-19

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Afula, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2023-12-18

Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsNemtabrutinib·Ibrutinib·Acalabrutinib

Merck Sharp & Dohme LLC

Phase 3

1,200

Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tsrifin

2023-12-13

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Bendamustine

Regeneron Pharmaceuticals

Phase 3

822

Ashdod, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2023-12-12

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05995353Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

110

Petah Tikva, Jerusalem

2023-12-11

Active, closed

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib

Hoffmann-La Roche

Phase 3

1,050

Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2023-12-11

Active, closed

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958Endometrial Cancer

DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

710

Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2023-12-06

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716NASH With Fibrosis, MASH With Fibrosis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

1,650

Petah Tikva, Ramat Gan, Haifa, Afula, Nahariya, Nazareth, Jerusalem, Tel Aviv

2023-12-01

Active, closed

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

NCT06097364Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Cytoxan

Regeneron Pharmaceuticals

Phase 3

733

Jerusalem, Beersheba, Haifa, Petah Tikva, Tel Aviv

2023-11-14

Recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

NCT05658640Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory

DrugsTrametinib·Cytarabine·Dexamethasone·Cyclophosphamide

Princess Maxima Center for Pediatric Oncology

Phase 1/2

Petah Tikva, Ramat Gan

2023-11-14

Recruiting

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

NCT05319353Cytomegalovirus (CMV)

DrugMaribavir

Takeda

Phase 3

Ramat Gan, Tel Aviv, Haifa, Petah Tikva

2023-11-13

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT06074588Non-small Cell Lung Cancer (NSCLC)

DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

556

Haifa, Jerusalem, Petah Tikva

2023-11-12

Active, closed

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT06161571NASH/MASH, NAFLD/MASLD

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

700

Petah Tikva, Ramat Gan, Haifa, Afula, Nahariya, Nazareth, Jerusalem, Tel Aviv

2023-11-10

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

NCT06084481Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma

DrugsTelisotuzumab Adizutecan·Itraconazole·Bevacizumab

AbbVie

Phase 1

325

Petah Tikva, Ramat Gan, Tel Aviv, Haifa, Jerusalem

2023-11-09

Active, closed

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT06122779Heart Failure

DrugBMS-986435

Bristol-Myers Squibb

Phase 2

227

Jerusalem, Beersheba, Be’er Ya‘aqov, Haifa, Petah Tikva, Rehovot, Safed

2023-11-07

Active, closed

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

NCT06087835Chronic Kidney Disease With High Proteinuria

DrugDapagliflozin

AstraZeneca

Phase 3

1,835

Ashkelon, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan, Rehovot

2023-11-07

Active, closed

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907Ulcerative Colitis

DrugUpadacitinib

AbbVie

Phase 3

122

Petah Tikva, Jerusalem

2023-11-06

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626Metastatic Breast Cancer

DrugsAbemaciclib·Fulvestrant

LeonaBio

Phase 3

600

Afula, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Rehovot, Tel Aviv

2023-10-31

Recruiting

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease

DrugTreprostinil

United Therapeutics

Phase 3

698

Ashkelon, Hadera, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Rehovot, Tel Aviv

2023-10-30

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Rehovot, Beersheba, Haifa, Be’er Ya‘aqov, Tel Aviv, Jerusalem, Petah Tikva

2023-10-25

Active, closed

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059Ulcerative Colitis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,109

Afula, Ashkelon, Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2023-10-25

Active, closed

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT06075667Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

160

Beer Yaacov, Petah Tikva, Ramat Gan, Jerusalem, Afula, Haifa, Beersheba

2023-10-16

Active, closed

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806Multiple Myeloma

DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan

Celgene

Phase 3

Petah Tikva, Ramat Gan, Beersheba, Tel Aviv, Haifa, Jerusalem

2023-10-16

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

Petah Tikva, Jerusalem, Ramat Gan, Tel Aviv, Haifa

2023-10-11

Recruiting

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037Lung Transplant Rejection

DrugsBelumosudil·Azithromycin

Sanofi

Phase 3

180

Petah Tikva

2023-10-10

Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

NCT05755386IC-MPGN

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

106

Haifa, Jerusalem, Petah Tikva

2023-10-02

Active, closed

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Gemcitabine·Cisplatin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

412

Jerusalem, Ramat Gan, Beersheba, Hafia, Kefar Sava, Petah Tikva, Tel Aviv

2023-09-22

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426Idiopathic Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,255

Haifa, Jerusalem, Petah Tikva, Rehovot, Tel Aviv

2023-09-14

Active, closed

Phosphate Urine Excretion in Critically Ill Patients

NCT06779331Critically Ill Intensive Care Unit Patients

Rabin Medical Center

Observational

205

Petah Tikva

2023-09-11

Recruiting

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

NCT05722938Community-acquired Pneumonia

Biotest

Phase 3

590

Beersheba, Haifa, Petah Tikva, Rehovot, Rishon LeZiyyon, Tel Aviv

2023-09-09

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617Primary Biliary Cholangitis

DrugSeladelpar

Gilead Sciences

Phase 3

402

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2023-09-07

Recruiting

Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population

NCT05837884Healthy

Tel-Aviv Sourasky Medical Center

Observational

2,000

Beersheba, Haifa, Petah Tikva, Tel Aviv

2023-09-05

Recruiting

Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer

NCT05502913Metastatic Lung Cancer

DrugRifaximin

Soroka University Medical Center

Phase 2

Beersheba, Petah Tikva

2023-09-01

Recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

NCT06016842Primary Biliary Cholangitis (PBC)

DrugElafibranor

Ipsen

Phase 3

276

Beersheba, Haifa, Jerusalem, Nahariya, Petah Tikva

2023-08-31

Active, closed

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

NCT06052267Asthma

DrugAlbuterol sulfate

Teva Branded Pharmaceutical Products R&D LLC

Phase 3

2,769

Ashkelon, Beersheba, Haifa, Jerusalem, Petach Tikvah, Petah Tikva, Rehovot, Tel Aviv

2023-08-30

Recruiting

A Smartphone Application for Added Psychological Wellbeing in Crohn's Disease

NCT06221254Crohn Disease

Soroka University Medical Center

Not applicable

200

Beersheba, Haifa, Petah Tikva, Ramat Gan

2023-08-01

Recruiting

V-Lap System For Wirelessly Measuring And Monitoring Left Atrial Pressure (LAP) In Patients With Advance Chronic Heart Failure

NCT05448833Heart Failure

Vectorious Medical Technologies Ltd.

Not applicable

Petah Tikva

2023-07-31

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Afula, Jerusalem, Petah Tikva, Ramat Gan

2023-07-19

Recruiting

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

NCT05980949Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1,000

Jerusalem, Ashkelon, Petah Tikva, Ramat Gan

2023-07-11

Active, closed

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

NCT05726227Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 3

212

Haifa, Petah Tikva, Tsrifin

2023-07-07

Active, closed

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

NCT05853367Metastatic Solid Tumors, Advanced Solid Tumors

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2023-07-06

Active, closed

Telepsychiatry to Enable Expedited Disposition of Psychiatric Emergencies

NCT05771545Psychiatric Emergency

Hebrew University of Jerusalem

Observational

959

Afula, Jerusalem, Pardés H̱anna Karkur, Petah Tikva, Safed, Tel Aviv, Tsur Moshe

2023-07-01

Active, closed

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

NCT05845814Metastatic Urothelial Carcinoma, Urothelial Neoplasms

DrugsPembrolizumab/Vibostolimab·Pembrolizumab/Favezelimab·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

390

Haifa, Petah Tikva, Ramat Gan

2023-06-23

Active, closed

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016Multiple Myeloma

DrugsIberdomide·Lenalidomide

Bristol-Myers Squibb

Phase 3

1,230

Ashdod, Beer Ya'Aqov, Hadera, Haifa, Jerusalem, Petah Tikva, Ramat Gan

2023-06-22

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

Petah Tikva, Safed, Ramat Gan, Tel Aviv, Haifa

2023-06-21

Active, closed

Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment

NCT05893498Percutaneous Coronary Intervention

CathWorks Ltd.

Not applicable

1,924

Petah Tikva

2023-06-21

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

NCT05789082Non-Small Cell Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 1/2

320

Haifa, Petah Tikva, Tel Aviv

2023-06-20

Active, closed

An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

NCT05841537Crohn's Disease

AbbVie

Observational

1,019

Jerusalem, Ramat Gan, Tel Aviv, Petah Tikva

2023-06-09

Active, closed

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566Small Cell Lung Cancer (SCLC)

DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan

Amgen

Phase 3

509

Haifa, Jerusalem, Kfar Saba, Petah Tikva

2023-05-31

Active, closed

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

NCT05881408Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc.

Phase 3

148

Petah Tikva, Tel Aviv

2023-05-31

Active, closed

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05809531C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis

DrugPegcetacoplan

Apellis Pharmaceuticals, Inc.

Phase 3

100

Petah Tikva

2023-05-29

Recruiting

FIH Study of the GEMINUS TAVI System in Patients With Severe Symptomatic Aortic Stenosis

NCT05909748Aortic Valve Stenosis

Valve Medical

Not applicable

Petah Tikva, Tel Aviv

2023-05-21

Recruiting

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786Myositis

Pfizer

Phase 3

318

Petah Tikva, Ramat Gan, Tel Aviv

2023-05-20

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

NCT05748171ACUTE LYMPHOBLASTIC LEUKEMIA

DrugInotuzumab Ozogamicin

Pfizer

Phase 2

100

Petah Tikva, Ramat Gan, Haifa, Tel Aviv

2023-05-17

Recruiting

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT05442567Ulcerative Colitis, Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

240

Jerusalem, Beersheba, Haifa, Petah Tikva

2023-05-16

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol

Gilead Sciences

Phase 3

654

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2023-05-08

Recruiting

Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease

NCT05599347Crohn's Disease Relapse, Biological Substance; Adverse Effect

Rambam Health Care Campus

Phase 2

180

Haifa, Beersheba, Holon, Jerusalem, Kiryat Bialik, Petah Tikva

2023-04-24

Active, closed

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

NCT05757102Asthma

DrugFF/UMEC/VI

GlaxoSmithKline

Phase 3

138

Ashkelon, Haifa, Petah Tikva

2023-04-24

Recruiting

POST URS Chemotherapy Instillation

NCT06167057UTUC

Carmel Medical Center

Not applicable

264

Ashdod, Beersheba, Be’er Ya‘aqov, Haifa, Petah Tikva, Rehovot, Safed, Tel Aviv

2023-04-17

Active, closed

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

NCT05757869Atrial Fibrillation

DrugsMilvexian·Apixaban

Janssen Research & Development, LLC

Phase 3

20,284

Afula, Hadera, Haifa, Holon, Jerusalem, Kfar Saba, Nazareth, Petah Tikva

2023-04-11

Active, closed

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma

AbbVie

Phase 1

Beer Ya'akov, Petah Tikva, Jerusalem, Ramat Gan

2023-04-04

Active, closed

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05572515Multiple Myeloma

DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib

Janssen Research & Development, LLC

Phase 3

614

Hadera, Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2023-03-29

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

NCT05646836Multiple Myeloma

DrugsCevostamab·Tocilizumab

Genentech, Inc.

Phase 1

Petah Tikva, Tel Aviv

2023-03-21

Recruiting

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632Multiple Myeloma

DrugEtentamig

AbbVie

Phase 1

250

Petah Tikva, Jerusalem, Ramat Gan, Tel Aviv

2023-03-21

Active, closed

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

NCT05612035Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease

Merck Sharp & Dohme LLC

Phase 2

129

Haifa, Petah Tikva

2023-03-16

Recruiting

Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

NCT05201404Hepatocellular Carcinoma, Cirrhosis

DrugNamodenoson

Can-Fite BioPharma

Phase 3

471

Petah Tikva

2023-03-15

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

Holon, Kfar Saba, Petah Tikva, Rehovot, Ramat Gan, Tel Aviv, Haifa, Jerusalem

2023-03-15

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

Petah Tikva, Rehovot

2023-03-03

Active, closed

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma

DrugsTovorafenib·Carboplatin

Day One Biopharmaceuticals, Inc.

Phase 3

418

Petah Tikva, Ramat Gan

2023-02-27

Active, closed

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034Ischemic Stroke; Ischemic Attack, Transient

DrugMilvexian

Janssen Research & Development, LLC

Phase 3

12,523

Beersheba, Haifa, Jerusalem, Naharya, Petah Tikva, Ramat Gan, Safed, Tel Aviv

2023-02-15

Active, closed

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976Diffuse Large B-Cell Lymphoma

DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone

Genmab

Phase 3

900

Kfar Saba, Tel Aviv, Haifa, Jerusalem, Ramat Gan, Petah Tikva

2023-02-08

Active, closed

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

NCT05609968Carcinoma, Non-Small-Cell Lung

DrugsSacituzumab Govitecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Jerusalem, KfarSaba, Petah Tikva, Tel Aviv, Tsrifin

2023-02-06

Active, closed

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack

DrugDexpramipexole Dihydrochloride

Areteia Therapeutics

Phase 3

600

Ashkelon, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2023-01-30

Active, closed

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

NCT05563220Breast Cancer, Metastatic Breast Cancer

DrugsAlpelisib·Capivasertib·Elacestrant·Everolimus

Stemline Therapeutics, Inc.

Phase 1/2

435

Ashdod, Haifa, Jerusalem, Petah Tikva, Ramat Gan

2023-01-24

Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

NCT05580562H3 K27M, Glioma

DrugDordaviprone

Jazz Pharmaceuticals

Phase 3

510

Ramat Gan, Beersheba, Haifa, Jerusalem, Petah Tikva, Petah Tikvah, Tel Aviv

2023-01-23

Recruiting

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

NCT05587712Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

Petah Tikva, Ramat Gan

2023-01-19

Active, closed

ABTECT - Maintenance

NCT05535946Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 3

1,116

Afula, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2023-01-16

Recruiting

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms

DrugsVepugratinib·Digoxin·Enfortumab Vedotin·Rosuvastatin

Eli Lilly and Company

Phase 1

677

Petah Tikva, Tel HaShomer

2023-01-12

Recruiting

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

NCT05658575Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis

DrugDapansutrile

Olatec Therapeutics, Inc.

Phase 2/3

300

Afula, Haifa, Petah Tikva, Ramat Gan

2023-01-06

Recruiting

International Rare Brain Tumor Registry

NCT05697874Astroblastoma, BCOR ITD Sarcoma, CNS Sarcoma, Unclassified Tumor, Malignant

Children's National Research Institute

Observational

5,800

Haifa, Petah Tikva, Tel Aviv, Tel HaShomer

2023-01-01

Active, closed

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

Kfar Saba, Petah Tikva

2022-12-30

Recruiting

Two-fraction Versus Five-fraction Stereotactic Radiotherapy for Localized Prostate Cancer

NCT06027892PROSTATE CANCER

Rabin Medical Center

Not applicable

562

Petah Tikva

2022-12-29

Recruiting

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

NCT05327894Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia

DrugBlinatumomab

Princess Maxima Center for Pediatric Oncology

Phase 3

160

Petah Tikva

2022-12-15

Active, closed

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

NCT05675449Multiple Myeloma

DrugsElranatamab·Carfilzomib

Pfizer

Phase 1

Haifa, Jerusalem, Petah Tikva

2022-12-14

Active, closed

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

NCT05681351Severe Hypertriglyceridemia

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

885

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2022-12-13

Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450Viral Lung Infection and Acute Respiratory Failure

DrugTozorakimab

AstraZeneca

Phase 3

3,527

Afula, Ashkelon, Beersheba, Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan

2022-12-13

Active, closed

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT05538130Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer

DrugPF-07799933

Pfizer

Phase 1

148

Petah Tikva, Ramat Gan, Jerusalem, Beersheba

2022-11-30

Active, closed

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Observational

6,000

Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Tel Aviv

2022-11-21

Active, closed

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3

260

Hadera, Haifa, Petah Tikva

2022-11-21

Active, closed

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

NCT05562830Urothelial Carcinoma

DrugsMK-3120·Zilovertamab vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

Haifa, Petah Tikva, Ramat Gan

2022-11-16

Recruiting

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428Carcinoma, Non-small-Cell Lung

DrugsLMWH·Direct Anticoagulant·DOAC·Low molecular weight heparin

Janssen Research & Development, LLC

Phase 2

520

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2022-11-11

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020Multiple Myeloma

DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide

Pfizer

Phase 3

1,060

Petah Tikva, Ramat Gan, Jerusalem, Beersheba, Tel Aviv

2022-11-10

Active, closed

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

NCT05583227Eosinophilic Esophagitis

DrugTezepelumab

AstraZeneca

Phase 3

368

Holon, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer

2022-11-10

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283Chronic Kidney Disease, Proteinuria, Children

DrugFinerenone

Bayer

Phase 3

100

Beersheba, Jerusalem, Nahariya, Petah Tikva, Tel Aviv

2022-11-08

Active, closed

Japan FFRangio Clinical Outcomes Study

NCT05648396Coronary Artery Disease

Rabin Medical Center

Observational

2,500

Petah Tikva

2022-11-07

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-10-25

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Afula, Be’er Ya‘aqov, Hadera, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan

2022-10-13

Active, closed

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237Non-small Cell Lung Cancer

DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed

Gilead Sciences

Phase 3

1,021

Jerusalem, Nahariya, Petah Tikva, Tel Aviv

2022-10-12

Active, closed

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

NCT05556512Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

15,374

Ashkelon, Haifa, Holon, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan

2022-10-11

Active, closed

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

NCT05514054Breast Neoplasms

DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole

Eli Lilly and Company

Phase 3

8,000

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2022-10-04

Active, closed

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

NCT05206357Non-hodgkin Lymphoma

DrugEpcoritamab

Genmab

Phase 1

Petah Tikva, Haifa, Ramat Gan

2022-10-04

Recruiting

Met Non Small Cell Cancer Registry (MOMENT)

NCT05376891Cancer

EMD Serono Research & Development Institute, Inc.

Observational

700

Afula, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-10-04

Active, closed

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease

DrugGuselkumab

Janssen-Cilag Ltd.

Phase 3

288

Afula, Haifa, Jerusalem, Petah Tikva

2022-09-27

Active, closed

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma

NCT05323253Recurrent Squamous Cell Carcinoma

Alpha Tau Medical LTD.

Not applicable

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2022-09-21

Active, closed

NCT05409066Follicular Lymphoma (FL)

DrugsEpcoritamab·Lenalidomide·Rituximab

Genmab

Phase 3

549

Tsrifin, Jerusalem, Safed, Ramat Gan, Tel Aviv, Haifa, Petah Tikva

2022-09-20

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Colitis, Ulcerative

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

577

Afula, Haifa, Jerusalem, Petah Tikva, Rehovot, Tel Aviv, Tel HaShomer, Tzrifin

2022-09-19

Active, closed

Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

NCT05399992Primary Hypercholesterolemia, Mixed Dyslipidemia

Novartis Pharmaceuticals

Observational

847

Holon, Petah Tikva, Tel Aviv

2022-09-12

Active, closed

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

NCT05243797Multiple Myeloma

DrugsTeclistamab·Lenalidomide

European Myeloma Network B.V.

Phase 3

1,594

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-09-08

By invitation

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis

DrugTreprostinil

United Therapeutics

Phase 3

1,850

Rehovot, Hadera, Jerusalem, Ashkelon, Ramat Gan, Haifa, Kfar Saba, Petah Tikva

2022-09-06

Active, closed

IonMAN Trial- First in Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

NCT05364697Coronary Stenosis, Coronary Disease, Non-ST Elevated Myocardial Infarction, Cardiovascular Diseases

Medinol Ltd.

Not applicable

Kfar Saba, Petah Tikva, Tel Aviv

2022-08-30

Recruiting

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

NCT05156983Coagulation Disorder

Takeda

Phase 3

440

Beer Yaacov, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-08-24

Active, closed

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395Extensive Stage Small Cell Lung Cancer

DrugsTarlatamab·Tecentriq·Etoposide·Atezolizumab

Amgen

Phase 1

184

Haifa, Jerusalem, Petah Tikva, Ramat Gan

2022-08-24

Active, closed

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2/3

1,856

Afula, Beersheba, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-08-22

Active, closed

An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

NCT05494606Ulcerative Colitis

AbbVie

Observational

785

Beer Ya'akov, Haifa, Beersheba, Tel Aviv, Petah Tikva

2022-08-15

Active, closed

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS

DrugsNorditropin·Somapacitan

Novo Nordisk A/S

Phase 3

412

Beersheba, Haifa, Petah Tikva, Tel HaShomer, Tsrifin

2022-08-10

Active, closed

A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

NCT05468697Renal Cell Carcinoma

DrugsBelzutifan·Palbociclib

Merck Sharp & Dohme LLC

Phase 1/2

Afula, Haifa, Jerusalem, Petah Tikva, Tel Aviv

2022-08-10

Active, closed

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 3

418

Haifa, Kfar Saba, Petah Tikva, Ramat Gan, Yeruham

2022-08-05

Active, closed

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

NCT05433584Type 2 Diabetes

DrugTirzepatide

Eli Lilly and Company

Phase 4

780

Holon, Petah Tikva, Ramat Gan, Rehovot, Jerusalem, Haifa, Sakhnin, Atlit

2022-08-01

Active, closed

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286Triple Negative Breast Cancer, PD-L1 Positive

DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel

Gilead Sciences

Phase 3

443

Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Rehovot, Tel Aviv

2022-07-25

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471Crohn's Disease

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

703

Afula, Haifa, Jerusalem, Petah Tikva, Rehovot, Tel Aviv, Tel HaShomer, Tzrifin

2022-07-22

Active, closed

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299Triple Negative Breast Cancer, PD-L1 Negative

DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine

Gilead Sciences

Phase 3

623

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Rehovot, Tel Aviv

2022-07-20

Recruiting

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

NCT04918173Congenital Antithrombin Deficiency

Octapharma

Phase 3

Petah Tikva, Ramat Gan

2022-07-01

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720Non-Hodgkin Lymphoma

DrugsGolcadomide·Epcoritamab·Polatuzumab Vedotin·Doxorubicin Hydrochloride

Genmab

Phase 2

264

Petah Tikva, Jerusalem, Ramat Gan, Tel Aviv

2022-06-14

Recruiting

Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML

NCT05477589Acute Myeloid Leukemia (AML) in Remission, Stem Cell Transplantation

Vastra Gotaland Region

Phase 3

170

Petah Tikva

2022-06-07

Recruiting

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

NCT05076175Colitis, Ulcerative

DrugOzanimod

Bristol-Myers Squibb

Phase 2/3

120

Petah Tikva, Jerusalem, Haifa

2022-05-30

Active, closed

An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

NCT05300724Age-Related Macular Degeneration

Genentech, Inc.

Observational

400

Haifa, Jerusalem, Petah Tikva

2022-05-27

Active, closed

PASS of Paediatric Patients Initiating Selumetinib

NCT05388370Neurofibromatosis Type 1

AstraZeneca

Observational

124

Petah Tikva, Ramat Gan, Tel Aviv

2022-05-23

Recruiting

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml

DrugELVN-001

Enliven Therapeutics

Phase 1

250

Jerusalem, Nahariya, Petah Tikva

2022-05-22

Active, closed

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

NCT05155254Metastatic Melanoma, Unresectable Melanoma

DrugsIO102-IO103·Pembrolizumab

IO Biotech

Phase 3

407

Afula, Beersheba, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer

2022-05-17

Active, closed

ALTERRA Post-Approval Study

NCT05378386Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation

Edwards Lifesciences

Observational

150

Petah Tikva

2022-05-12

Active, closed

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

NCT05269004Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 3

1,300

Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-05-03

Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

NCT04879329Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Pembrolizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

372

Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2022-05-03

Active, closed

Evolut™ EXPAND TAVR II Pivotal Trial

NCT05149755Moderate Aortic Valve Stenosis

Medtronic Cardiovascular

Not applicable

650

Jerusalem, Petah Tikva

2022-04-27

Active, closed

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs

DrugsAbiraterone·Abemaciclib·Prednisolone·Prednisone

Eli Lilly and Company

Phase 3

925

Kfar Saba, Petah Tikva, Ramat Gan, Tsrifin, Jerusalem, Haifa, Tel Aviv

2022-04-14

Active, closed

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

NCT05316155Non-Muscle Invasive Bladder Neoplasms

DrugErdafitinib

Janssen Research & Development, LLC

Phase 1/2

235

Haifa, Petah Tikva, Tel Aviv

2022-04-11

Active, closed

A Study of Rusfertide in Adults With Polycythemia Vera (PV)

NCT05210790Polycythemia Vera

DrugRusfertide

Protagonist Therapeutics, Inc.

Phase 3

293

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Tel Aviv, Tsrifin

2022-04-11

Active, closed

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035Chronic Kidney Disease, Proteinuria

DrugFinerenone

Bayer

Phase 3

219

Petah Tikva, Nahariya, Beersheba, Jerusalem, Tel Aviv

2022-03-28

Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

NCT04895436Chronic Lymphocytic Leukemia (CLL)

DrugsVenclexta·Obinutuzumab·Venetoclax

AbbVie

Phase 2

Jerusalem, Ramat Gan, Tel Aviv, Petah Tikva

2022-03-28

Active, closed

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577Prostate Cancer

DrugsCapivasertib·Docetaxel

AstraZeneca

Phase 3

1,035

Be’er Ya‘aqov, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2022-03-25

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Petah Tikva, Ramat Gan, Jerusalem, Haifa, Beersheba, Tel Aviv

2022-03-25

Active, closed

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

530

Ashkelon, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva

2022-03-15

Active, closed

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728Carcinoma, Renal Cell

DrugsBelzutifan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,800

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-03-15

Active, closed

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

NCT05169567Breast Neoplasm, Neoplasm Metastasis

DrugsAbemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

368

Kfar Saba, Petah Tikva, Ramat Gan, Jerusalem, Beersheba, Tel Aviv

2022-03-11

Active, closed

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 3

799

Ashdod, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2022-03-10

Active, closed

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures

DrugFintepla

Zogenix, Inc.

Phase 3

Petah Tikva, Ramat Gan, Tel Aviv

2022-03-08

Recruiting

Staphylococcus Aureus Network Adaptive Platform Trial

NCT05137119Staphylococcus Aureus Bacteremia

DrugsDaptomycin·Benzylpenicillin·Clindamycin·Cefazolin

University of Melbourne

Phase 4

8,000

Haifa, Petah Tikva, Ramat Gan

2022-02-16

Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

NCT04779320Crohn's Disease (CD)

DrugVedolizumab

Takeda

Phase 3

120

Petah Tikva, Jerusalem, Beersheba, Haifa

2022-02-10

Active, closed

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

NCT05202509Atherosclerotic Cardiovascular Disease

DrugObicetrapib

NewAmsterdam Pharma

Phase 3

9,541

Ashkelon, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Poria – Neve Oved, Rehovot

2022-02-07

Active, closed

Post Marketing Clinical Follow Up of the BioProtect Balloon Implant System

NCT05354440Prostate Cancer

BioProtect

Observational

Ashdod, Petah Tikva

2022-01-01

Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor

DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab

Exelixis

Phase 1

1,394

Beersheba, Haifa, Jerusalem, Petah Tikva, Tel Aviv, Tsrifin

2021-12-14

Active, closed

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

DrugsZirabev·Taxotere·Avastin·Keytruda

Merck Sharp & Dohme LLC

Phase 3

643

Afula, Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2021-12-13

Active, closed

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

NCT05030428Atherosclerotic Cardiovascular Disease

DrugInclisiran sodium

Novartis Pharmaceuticals

Phase 3

17,004

Ashdod, Holon, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Sefad, Tsrifin

2021-11-23

Active, closed

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

776

Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2021-11-17

Active, closed

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

DrugBlinatumomab

Amgen

Phase 3

303

Haifa, Jerusalem, Petah Tikva

2021-11-02

Recruiting

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT05005403Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer

DrugsBudigalimab·Telisotuzumab Adizutecan·Bevacizumab

AbbVie

Phase 1

694

Beer Ya'akov, Kefar Sava, Petah Tikva, Ramat Gan, Tel Aviv, Haifa, Jerusalem

2021-11-01

Active, closed

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

NCT05043090Papillary Renal Cell Carcinoma

DrugsSavolitinib·Sunitinib·Durvalumab

AstraZeneca

Phase 3

148

Haifa, Petah Tikva

2021-10-28

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

430

Petah Tikva, Ramat Gan

2021-10-25

Active, closed

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04861259Atypical Hemolytic Uremic Syndrome

DrugCrovalimab

Hoffmann-La Roche

Phase 3

Haifa, Petah Tikva, Ramat Gan

2021-10-22

Recruiting

Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors

NCT06940349Solid Tumors Refractory to Standard Therapy

DrugsSunitinib·Palbociclib

Rabin Medical Center

Phase 1/2

100

Petah Tikva

2021-10-21

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 1

520

Kfar Saba, Jerusalem, Ramat Gan, Tel Aviv, Haifa, Petah Tikva

2021-10-13

Recruiting

Deep Brain Stimulation Surgery for the Treatment of Refractory Obsessive-Compulsive Disorder

NCT05995951Obsessive-Compulsive Disorder

Rabin Medical Center

Not applicable

Petah Tikva

2021-10-12

Active, closed

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

DrugsBosutinib·Asciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

405

Petah Tikva, Ramat Gan, Tel Aviv

2021-10-06

Active, closed

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT04926818Multiple Sclerosis (MS)

DrugsSiponimod·Fingolimod·Ofatumumab

Novartis Pharmaceuticals

Phase 3

129

Petah Tikva

2021-10-05

Active, closed

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

NCT05059522Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer

DrugsCMP 001·Utomilumab·Talazoparib·Axitinib

Pfizer

Phase 3

Petah Tikva

2021-09-29

Recruiting

ContraBand™: Safety & Feasibility Study (RM-20-01)

NCT05230745Heart Failure, Left Sided

Restore Medical Ltd

Not applicable

Nahariya, Petah Tikva, Rehovot

2021-09-28

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136Primary Biliary Cholangitis, PBC

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

333

Hadera, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2021-09-22

Active, closed

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

600

Haifa, Nahariya, Petah Tikva, Rehovot, Tel Aviv

2021-09-20

Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462Primary IgA Nephropathy

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

540

Ashkelon, Jerusalem, Petah Tikva

2021-09-20

Active, closed

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

NCT04938817Small Cell Lung Carcinoma

DrugsMK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab·R-DXd

Merck Sharp & Dohme LLC

Phase 1/2

110

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2021-08-19

By invitation

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

NCT04957719Acute Myocardial Infarction

Viatris Innovation GmbH

Phase 3

25,000

Beersheba, Hadera, Haifa, Holon, Jerusalem, Kfar Saba, Nahariya, Petah Tikva

2021-08-14

Active, closed

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

NCT04624230Ulcerative Colitis

DrugTofacitinib

Pfizer

Phase 3

118

Be’er Ya‘aqov, Haifa, Jerusalem, Petah Tikva, Tel Aviv

2021-08-12

Recruiting

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

NCT04817618C3G

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

Petah Tikva

2021-07-28

Active, closed

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04961567Lupus Erythematosus, Systemic

DrugLitifilimab

Biogen

Phase 3

562

Haifa, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2021-07-16

Active, closed

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

NCT04657289Neovascular Age-related Macular Degeneration (nAMD)

DrugRanibizumab

Hoffmann-La Roche

Phase 3

451

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Rehovot, Tel Aviv

2021-07-14

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Ribociclib·Abemaciclib

AstraZeneca

Phase 3

315

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan

2021-06-30

Active, closed

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755Neoplasms, Breast

DrugNiraparib

GlaxoSmithKline

Phase 3

Beersheba, Haifa, Jerusalem, Petah Tikva, Rehovot, Tel Aviv

2021-06-28

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

NCT04802759Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

DrugsSamuraciclib·Ipatasertib·Phesgo·Giredestrant

Hoffmann-La Roche

Phase 1/2

316

Jerusalem, Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2021-06-22

Active, closed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098Arthritis, Psoriatic

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

1,054

Ashkelon, Haifa, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2021-06-17

Recruiting

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer

DrugsImzokitug·Pumitamig·Nivolumab·Docetaxel

Bristol-Myers Squibb

Phase 1/2

1,109

Petah Tikva, Ramat Gan, Haifa, Tel Aviv

2021-05-27

Recruiting

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

150

Beersheba, Haifa, Jerusalem, Petah Tikva, Tsrifin

2021-05-26

Active, closed

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

NCT04637763Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma

DrugsFludarabine·Cyclophosphamide

Caribou Biosciences, Inc.

Phase 1

Tel Aviv, Jerusalem, Petah Tikva, Tel HaShomer

2021-05-26

Active, closed

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel

Daiichi Sankyo

Phase 3

490

Be'er-Sheva Southern, Petah Tikva, Ramat Gan

2021-05-21

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 3

815

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2021-05-12

Active, closed

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

NCT04824092Diffuse Large B-cell Lymphoma

DrugsTafasitamab·Vincristine·Doxorubicin·Prednisone

Incyte Corporation

Phase 3

899

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2021-05-11

Active, closed

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

NCT04764188NSCLC

DrugAlectinib

Hoffmann-La Roche

Observational

800

Haifa, Petah Tikva, Ramat Gan, Tel Aviv

2021-05-10

Active, closed

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715Breast Cancer; HER2-positive; Metastatic

DrugsPertuzumab·Trastuzumab deruxtecan·Trastuzumab

AstraZeneca

Phase 3

1,157

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2021-04-26

Active, closed

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

NCT04770896Unresectable Hepatocellular Carcinoma

DrugsSorafenib·Tecentriq·Atezolizumab·Lenvatinib

Hoffmann-La Roche

Phase 3

557

Haifa, Petah Tikva, Tel Aviv

2021-04-26

Recruiting

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

NCT04775485Low-grade Glioma, Advanced Solid Tumor

DrugTovorafenib

Day One Biopharmaceuticals, Inc.

Phase 2

141

Haifa, Petah Tikva, Ramat Gan

2021-04-22

Active, closed

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124Bladder Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

808

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv, Tsrifin

2021-04-21

Active, closed

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma

DrugsTafasitamab·Lenalidomide·Rituximab

Incyte Corporation

Phase 3

654

Afula, Bear Sheva, BEER Yaaqov, Holon, Jerusalem, Kfar Saba, Petah Tikva, Tel HaShomer

2021-04-15

Active, closed

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

DrugsPelabresib·Ruxolitinib

Novartis Pharmaceuticals

Phase 3

430

Beersheba, Be’er Ya‘aqov, Haifa, Holon, Jerusalem, Nahariya, Petah Tikva, Tel Aviv

2021-04-09

Recruiting

Screening for Islet Autoantibodies in the Israeli Paediatric General Population for Detection of Pre-symptomatic Type-1 Diabetes Mellitus

NCT04834518Type1diabetes

Rabin Medical Center

Observational

50,000

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2021-04-01

Active, closed

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT04822181Non-alcoholic Steatohepatitis

DrugSemaglutide

Novo Nordisk A/S

Phase 3

1,205

Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2021-04-01

Active, closed

Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

NCT04790474Multiple Myeloma in Relapse, Refractory Multiple Myeloma

Tel-Aviv Sourasky Medical Center

Phase 2

Afula, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2021-03-25

Active, closed

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

NCT04817007Myelofibrosis

DrugsBMS-986158·Fedratinib·Ruxolitinib

Bristol-Myers Squibb

Phase 1/2

216

Beersheba, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2021-03-22

Active, closed

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsIdelalisib·Truxima·Pirtobrutinib·Bendamustine

Loxo Oncology, Inc.

Phase 3

238

Petah Tikva, Beersheba, Netanya, Tel Aviv, Haifa

2021-03-09

Recruiting

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

NCT04777994Advanced Solid Tumor Cancer

Calico Life Sciences LLC

Phase 1

248

Petah Tikva, Jerusalem, Ramat Gan

2021-03-09

Active, closed

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

NCT04775082Obesity

DrugLiraglutide

Novo Nordisk A/S

Phase 3

Haifa, Petah Tikva

2021-03-04

Recruiting

Prospective Validation of the OHI Index

NCT05882175HLH, Hemophagocytic Lymphohistiocytoses, Hemophagocytic Syndrome, Hematologic Malignancy

Meir Medical Center

Observational

300

Kfar Saba, Petah Tikva

2021-03-03

Active, closed

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

NCT04608318Chronic Lymphoid Leukemia

DrugsIbrutinib·Obinutuzumab·Venetoclax

German CLL Study Group

Phase 3

897

Beersheba, Be’er Ya‘aqov, Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Ramat Gan

2021-03-01

Active, closed

Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients Who Completed 12 Months of Follow-Up Post Implantation (Continuation Study for Study BM-011-IL)

NCT05330520BPH, BOO - Bladder Outflow Obstruction, Enlarged Prostate (BPH)

Butterfly Medical Ltd.

Not applicable

Petah Tikva, Safed

2021-02-10

Active, closed

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

NCT04589845Solid Tumors

DrugsCamonsertib·Belvarafenib·Pralsetinib·Divarasib

Hoffmann-La Roche

Phase 2

920

Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2021-01-18

Active, closed

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877Endometrial Neoplasms

DrugsKeytruda·Docetaxel·Paclitaxel·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

990

Haifa, Holon, Jerusalem, Petah Tikva, Ramat Gan

2021-01-10

Active, closed

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

NCT04521231B Cell Precursor Acute Lymphoblastic Leukemia

DrugBlinatumomab

Amgen

Phase 1/2

181

Haifa, Petah Tikva

2021-01-04

Active, closed

Effectiveness of WhatsApp Education and Support Messages for Urolithiasis Prevention

NCT05627622Urinary Tract Stone

Rabin Medical Center

Not applicable

200

Petah Tikva

2021-01-01

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

NCT04663308Primary Sclerosing Cholangitis

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

182

Hadera, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tel Aviv

2020-12-18

Active, closed

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib·Pemetrexed·Cisplatin

AstraZeneca

Phase 3

358

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2020-12-16

Active, closed

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

NCT04490915Congenital Adrenal Hyperplasia

DrugCrinecerfont

Neurocrine Biosciences

Phase 3

182

Afula, Beersheba, Petah Tikva, Tel Aviv

2020-12-16

Active, closed

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

DrugsTrastuzumab emtansine·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 3

1,600

Beersheba, Ramat Gan, Jerusalem, Petah Tikva

2020-12-04

Active, closed

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

NCT04540497IgG4 Related Disease

DrugInebilizumab

Amgen

Phase 3

135

Kfar Saba, Petah Tikva, Tel Aviv, Tel HaShomer

2020-12-04

Active, closed

Decoding Personalized Nutritional, Microbiome and Host Patterns Impacting Clinical and Prognostic Features in Crohn's Disease

NCT04283864Crohn Disease

Weizmann Institute of Science

Observational

267

Petah Tikva, Tel Aviv

2020-11-29

Active, closed

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

NCT04623541Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia

DrugsEpcoritamab·Pirtobrutinib·Lenalidomide·Venetoclax

Genmab

Phase 1/2

194

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2020-11-25

Active, closed

The ENCIRCLE Trial

NCT04153292Mitral Regurgitation, Mitral Valve Insufficiency

Edwards Lifesciences

Not applicable

786

Petah Tikva

2020-11-12

Active, closed

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235AL Amyloidosis

DrugsAnselamimab·Cyclophosphamide, bortezomib, and dexamethasone (CyBorD)

Alexion Pharmaceuticals, Inc.

Phase 3

281

Haifa, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer

2020-11-03

Active, closed

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

NCT04524871Advanced Liver Cancers

DrugsTobemstomig·ADG126·Tiragolumab·Tocilizumab

Hoffmann-La Roche

Phase 1/2

518

Haifa, Jerusalem, Petah Tikva, Tel Aviv

2020-11-01

Active, closed

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

NCT04464226Cancer

DrugDarolutamide

Bayer

Phase 3

774

Petah Tikva, Safed, Beersheba

2020-10-20

Active, closed

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

NCT04446117Metastatic Prostate Cancer, Prostate Adenocarcinoma

DrugsZytiga·Xtandi·Abiraterone·Abiraterone acetate

Exelixis

Phase 3

575

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Safed, Tel Aviv

2020-10-19

Active, closed

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

NCT04538664Carcinoma, Non-Small-Cell Lung

DrugsAmivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

308

Jerusalem, Kfar Saba, Petah Tikva, Tel Aviv

2020-10-13

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Palbociclib·Letrozole

Hoffmann-La Roche

Phase 3

992

Petah Tikva, Ramat Gan, Tel Aviv

2020-10-09

Active, closed

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

NCT04529772Diffuse Large B-Cell Lymphoma

DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone

Acerta Pharma BV

Phase 3

611

Afula, Ashdod, Beersheba, Haifa, Holon, Jerusalem, Nahariya, Petah Tikva

2020-10-08

Active, closed

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT04484623Multiple Myeloma

DrugsBelantamab mafodotin·Pomalidomide·Bortezomib·Dexamethasone

GlaxoSmithKline

Phase 3

302

Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Tel Aviv

2020-10-01

Active, closed

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04487080Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Osimertinib

Janssen Research & Development, LLC

Phase 3

1,074

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2020-09-30

Active, closed

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611Crohn's Disease (CD)

DrugsSkyrizi·Risankizumab·Ustekinumab

AbbVie

Phase 3

527

Tsrifin, Jerusalem, Ashkelon, Beersheba, Ramat Gan, Tel Aviv, Petah Tikva

2020-09-30

Recruiting

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

NCT04625907Rhabdomyosarcoma

DrugsActinomycin-D·Dactinomycin·Ifosfamide·Vinorelbine

University of Birmingham

Phase 1/2

1,672

Haifa, Jerusalem, Petah Tikva, Tel Aviv, Tel HaShomer

2020-09-17

Active, closed

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT04384484Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

DrugsLoncastuximab Tesirine·Rituximab·Oxaliplatin·Gemcitabine

ADC Therapeutics S.A.

Phase 3

440

Ashdod, Beersheba, Be’er Ya‘aqov, Haifa, Petah Tikva, Tel Aviv

2020-09-16

Active, closed

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

NCT04401748Myelodysplastic Syndrome (MDS)

DrugsVenclexta·Azacitidine·Venetoclax

AbbVie

Phase 3

531

Jerusalem, Ramat Gan, Tel Aviv, Haifa, Petah Tikva

2020-09-10

Active, closed

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022Relapsed/Refractory Diffuse Large B-cell Lymphoma

DrugsSelinexor·Rituximab·Dexamethasone·Gemcitabine

Karyopharm Therapeutics Inc

Phase 2/3

501

Ashdod, Beersheba, Petah Tikva, Tel Aviv

2020-09-03

Active, closed

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

NCT04221477Lupus Nephritis

DrugsDiphenhydramine·Acetaminophen·Methylprednisolone·Obinutuzumab

Hoffmann-La Roche

Phase 3

271

Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2020-08-10

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963Ovarian Cancer, Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

185

Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2020-08-04

Active, closed

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

NCT04509700B-Cell Malignancies

DrugsItacitinib·Parsaclisib·Ibrutinib·Ruxolitinib

Incyte Corporation

Phase 2

112

Jerusalem, Petah Tikva, Tel HaShomer

2020-08-03

Active, closed

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Advanced or Metastatic Breast Cancer

DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel

AstraZeneca

Phase 3

866

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tel Aviv

2020-07-24

Active, closed

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

NCT04191304Hypereosinophilic Syndrome

DrugBenralizumab

AstraZeneca

Phase 3

134

Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Rehovot, Tel Aviv

2020-07-20

Active, closed

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853Hormone-Sensitive Prostate Cancer

DrugsZytiga·Capivasertib·Abiraterone acetate

AstraZeneca

Phase 3

1,012

Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan, Tsrifin

2020-07-13

Recruiting

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

NCT04414475Multiple Myeloma, Refractory

DrugsVelcade·Selinexor·Bortezomib·Dexamethasone

Karyopharm Therapeutics Inc

Phase 2

127

Afula, Ashdod, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv, Ashkelon

2020-07-01

Active, closed

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

NCT04270409Plasma Cell Myeloma

DrugsMontelukast·Diphenhydramine·Acetaminophen·Isatuximab

Sanofi

Phase 3

337

Ashdod, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2020-06-16

Recruiting

Intra-wound Vancomycin Powder for Prevention of Surgical Site Infection Following Spinal Surgery

NCT05959603Infection

DrugVancomycin

Rabin Medical Center

Phase 3

363

Petah Tikva

2020-05-31

Active, closed

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

NCT04241185Urinary Bladder Neoplasms

DrugsMitomycin C·Fluorouracil·Adrucil·Keytruda

Merck Sharp & Dohme LLC

Phase 3

520

Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv

2020-05-19

Active, closed

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

NCT04214288Advanced ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Fulvestrant

AstraZeneca

Phase 2

240

Jerusalem, Nahariya, Petah Tikva

2020-04-22

Active, closed

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Fulvestrant

AstraZeneca

Phase 3

818

Afula, Beersheba, Haifa, Jerusalem, Kfar Saba, Petah Tikva, Ramat Gan

2020-04-16

Active, closed

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

NCT04223856Urothelial Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Astellas Pharma Global Development, Inc.

Phase 3

886

Beersheba, Haifa, Holon, Jerusalem, Kfar Saba, Petah Tikva, Rehovot, Tel Aviv

2020-03-30

Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Israeli investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 November 2026. https://priyalifescience.com/clinical-trials-israel/city/petah-tikva

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Israel and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,426 studies in total at the last sync on 12 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 616 of those studies with a site in Petah Tikva.

How many clinical trials are recruiting in Petah Tikva?

279 of the 616 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:18 UTC sync. A further 14 have not yet opened recruitment, 316 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Petah Tikva), 616 studies
Phase	Studies	Recruiting	Share
Phase 3	355	137	57.6%
Phase 2	73	36	11.9%
Phase 1/2	46	26	7.5%
Not applicable	44	23	7.1%
Observational	40	21	6.5%
Phase 2/3	25	19	4.1%
Phase 1	24	13	3.9%
Phase 4	8	3	1.3%
Early Phase 1	1	1	0.2%

Most active sponsors

Lead sponsors with the most studies (Petah Tikva)
Lead sponsor	Studies	Recruiting
Merck Sharp & Dohme LLC	63	34
AbbVie	46	18
AstraZeneca	40	12
Janssen Research & Development, LLC	37	14
Eli Lilly and Company	29	16
Hoffmann-La Roche	23	7
Rabin Medical Center	23	17
Pfizer	22	14
Novartis Pharmaceuticals	20	10
Bristol-Myers Squibb	15	8

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.